omega-3-acid ethyl esters
Commercial- Indications
- Cardiovascular disease, Post-myocardial infarction
Company intelligence / Profile preview
Pronova BioPharma developed and commercialized Omacor/Lovaza, a prescription omega‑3 fatty acid product approved in the US, Europe, and Asia for lowering triglyceride levels. The drug has demonstrated efficacy as both monotherapy and in combination with statins for cardiovascular risk reduction. At its peak, global sales exceeded $700 million annually[2][3].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pronova BioPharma.